All News

Article

Consequences of TNF inhibition (3.18.2022)

Jack Cush, MD Mar 18, 2022

This week we're going to talk about the downside of TNF inhibitors, a few interesting observations in gout, and yes, kids do get COVID. We're also going to preview what's coming in April (hint: it's about PsA). This and more as Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Article

Iberdomide in Systemic Lupus Erythematosus

Jack Cush, MD Mar 17, 2022

The NEJM reports that systemic lupus erythematosus (SLE) patients treated with iberdomide, a cereblon modulator, was effective at yielding a significant SRI-4 clinical response after 24 weeks.

Article

Seropositivity Linked to Bronchiectasis in Rheumatoid Arthritis

Jack Cush, MD Mar 17, 2022

Rheumatoid arthritis associated bronchiectasis (RA-BR) is uncommon, and is unrelated to interstitial lung disease (ILD), but like ILD, can substantially impact RA outcomes.

Welcome to #RNL2022 ! Not only are we in-person in Texas, we have people online from all over the US and Canada to New Zealand and Japan!

RheumNow Live is kicking off with a pod on Rheumatoid Arthritis - Future Improvements. Dr. Cush will lead the first presentation on Treatment Choices in Refractory RA. #RNL2022 https://t.co/H3RbDPZxM1

RheumNow Live is HERE. Welcome everyone! What pod are you looking forward to the most? Anyone out there who is still on the fence--virtual registration is still open. Join us! https://t.co/3wKgCKqvfD #RNL2022 https://t.co/W2hUpZ2Y8N

https://bit.ly/3ioDLCk

Seropositivity Linked to Bronchiectasis in Rheumatoid Arthritis Bronchiectasis in rheumatoid arthritis-associated (RA-BR) is uncommon, is unrelated to interstitial lung disease (ILD), but like ILD can substantially impact RA outcomes. https://t.co/xm8HWJkI5C https://t.co/JztHlzGw65

https://bit.ly/3KRKu43

Disappointment Behind Acute Gout Hospitalizations https://t.co/Hd1g5Kvwwr https://t.co/jYFVVOQOZX

https://bit.ly/3wgHwSv

Environmental Pollutants Ups Autoimmune Disease Risk An Italian environmental study shows that air pollution increases the risk of autoimmune diseases, in particular rheumatoid arthritis, CTDs and inflammatory bowel diseases (IBD). https://t.co/LVCn8zgdpG https://t.co/wzi2GzSmGY

https://bit.ly/3IlixjF

Medscapes 2022 Physician Suicide report. Sadly 10% of MDs have considered suicide. Highest in pathology (13%), surgery (12%), oncology (12%), ID (11%), EM(11%). LOWEST in Rheumatology (5%), nephrology (2%) https://t.co/ER8kNfcPEh https://t.co/cWQobpIO97

https://wb.md/3wgl646

Happy Match Day to all newly matched doctors! We can't wait to see who becomes a rheumatologist in a few years. Enjoy your residency and celebrate your amazing accomplishment today! https://t.co/Yuhu7ksmog

Among 98 women with axSpA, there were 335 pregnancies & 279 live births - 52% uncomplicated and 48% complicated (13%) multiple complications. axSpA had more Preterm birth (13 vs 5%), pre-eclampsia (7 vs 3%), Low birth Wt (8 vs 3%) https://t.co/i43HKduAgu https://t.co/XHbtH9YMrt

https://bit.ly/3Ihy3Na

Baricitinib has been studied in 15 relapsing GCA pts - prospective, open-label, BARI 4 mg/d w/ GC taper. 14/15 completed 52 wks; 13/15 went into remission and d/c steroids. There was 1 Bari D/C for adverse event & 1 pt w/ serious AE. 1 pt relapsed. https://t.co/J5bjdPAFdm https://t.co/LsuSVP8L0R

https://bit.ly/3theekZ

Psoriasis RCT studied ADA+MTX (31) vs ADA (30); after 12 mos, a (non-significant) better drug survival w/ ADA-MTX (74 vs 59%; p=0.15). Also favoring, but not signif was PASI 75 (58 vs 37%). Fewer anti-ADA Abs seen w/ ADA-MTX (23 vs 60%; p<0.01) https://t.co/9CAQrpl6hU https://t.co/mr0ZaJ9mbW

https://bit.ly/3IuPaeR

Frailty: a decline in the physiologic reserve & function of several systems, leading to increased vulnerability and adverse health outcomes. Not just age; increased in RA (33%) more than AS or PsA. Frailty is dynamic & potentially reversible https://t.co/82hkGKoRxV https://t.co/7d9sycC6S2

https://bit.ly/3wdyh5x

Infants and children do get COVID; all races, 35% w/ comorbidities. CDC study from 99 counties in 14 US states shows betw 3/20 & 2/22 there were 2,637 hospitalized infants & children 0–4 yrs old; 24% went to ICU; there were 18 deaths https://t.co/mWyXAj2GbT https://t.co/MYN37JKziD

https://bit.ly/36xamDG

Abbvie announced that the FDA has approved Rinvoq (upadacitinib) for use in adults with active ulcerative colitis (after failing TNFi); approval based on 3 endoscopic UC trials. Starting dose is 45 mg/d, then maintain w/ 15 mg (some can get 30 mg) https://t.co/ZUbnkR7LMY https://t.co/dE1JkxzkSz

https://bit.ly/37xK7x7

Another Rx for #PsA #psoriaticarthritis Deucravacitinib is shown to be effective. Good news but this adds to the dilemma of what to use in PsA Rx and in what order. Rational Rx may need #personalized Rx for best bang for buck! https://t.co/JQs7BlQwos

ARD & RMD Open on Twitter: "Selective inhibition of TYK2 with deucrava…

Individualized Therapy in Ankylosing Spondylitis Whether patients with AS would improve substantially with TNF inhibitor therapy was predicted with moderate to high accuracy based on a lab test and two measures of disease activity, researchers reported. https://t.co/hbbYqTiWGE https://t.co/Hx2U4y2e0F

https://bit.ly/3KFIL1M

Intravenous (IV) form of tramadol (Schedule IV) went in front of the FDA Drug Safety & Risk and Anesthetic/Analgesic Advisory Committees yesterday. They voted 14-8 against approval of IV tramadol (now available as tabs, liquid) https://t.co/AP2G7w8z1h https://t.co/lr9aLJSKi6

https://bit.ly/3tgn3vg

Topics

All News

Consequences of TNF inhibition (3.18.2022)

Iberdomide in Systemic Lupus Erythematosus

Seropositivity Linked to Bronchiectasis in Rheumatoid Arthritis

Do you get our email newsletter?